JointPromise Lunch and Learn:

Join us for an interactive and informative session at STEMCELL Technologies, Cambridge, UK. This in-person event is a great opportunity to network, learn, and enjoy a delicious lunch. Our experts will share updates around the Horizon 2020 Grant, JointPromise, as well as discuss state of the art research in regenerative medicine and automation. Register now to secure your spot!

Speakers

Ioannis Papantoniou (KU Leuven)

Judith Krieger (Fraunhofer IPT)

Douglas Kondro (STEMCELL Technologies)

For more information please register here

DATE & TIME:March 7th, 2024
9:30 am - 1:00 pm BST
Lunch will be provided for all participants.

About JointPromise

JointPromise is a Horizon 2020 consortium aiming to develop a cell therapy solution to treat osteochondral defects (acute damage to cartilage/ bone in a joint). These osteochondral defects provide an epicenter for further cartilage degeneration, so repair of these defects can cure or delay onset of disease. JointPromise aims to develop 3D printed microtissue constructs to regenerate the injury site. In order to be able to produce scaled-up implants containing at the same time a highly precise structure, integration of bioprinting technologies is needed. Moreover, in order to cover rising clinical demand the whole manufacturing process, which is mostly manual today, will need to be automated adopting robotics, bioprinting and bioreactor technologies. In order to demonstrate implant feasibility and efficacy, large osteochondral defect repair will be studied in the minipig, a large animal model relevant to the patient. Taken together we strive to develop an automated, GMP-grade platform producing large, patterned and vascularized joint implants providing also a paradigm shift for generic automated manufacturing of organoid-based tissue implants.